{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-116254","form_type":"8-K","ticker":"BCLI","cik":"0001137883","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.327677+00:00","generated_at":"2026-06-08T06:06:02.099304+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Brainstorm Cell Nasdaq delisting risk: MVLS below $35M minimum","bullets":["Received Nasdaq deficiency notice on Nov 6, 2023 for MVLS below $35M required for continued listing.","Has 180 calendar days, until May 6, 2024, to regain compliance; must close at $35M+ for 10 consecutive days.","Common stock continues trading under symbol BCLI on Nasdaq Capital Market during compliance period.","Company intends to take reasonable measures to regain compliance but no assurance of success.","If not compliant by May 6, 2024, Nasdaq may delist; appeal possible but uncertain."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-116254","json":"https://secwatch.observer/filing/0001104659-23-116254.json","markdown":"https://secwatch.observer/filing/0001104659-23-116254.md","text":"https://secwatch.observer/filing/0001104659-23-116254.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923116254/0001104659-23-116254-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923116254/tm2330353d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:06:02.099304+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f3e08327689ad1d8bfcb533e99947870e5e4962f","claim":"BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).","evidence_excerpt":"November 6, 2023, Brainstorm Cell Therapeutics Inc. (the “Company”) received a letter (the “MVLS Deficiency Notice”) from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that from September 25, 2023 to November 3, 2023, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). The MVLS Deficiency Notice has no immediate effect on the listing of the Company’s comm","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923116254/0001104659-23-116254-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5550(b)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}